Dechra Veterinary Products

Dechra is a global specialist veterinary pharmaceuticals and related products business focused on the development, manufacture, and marketing of high-value products for the animal health market. The company holds a leading position in several therapeutic areas, most notably endocrinology, where it provides market-standard treatments such as Vetoryl and Felimazole. Its portfolio also includes significant offerings in dermatology, analgesia, anesthesia, and cardiovascular medicine for both companion animals and livestock. Headquartered in the UK, Dechra operates a robust international distribution network and maintains internal manufacturing capabilities. In early 2024, the company was acquired by the private equity firm EQT, transitioning from a public entity to a private one to further accelerate its global growth strategy.